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Assessment of the nematocidal activity of
metallocenyl analogues of monepantel†
Jeannine Hess,a Malay Patra,a Abdul Jabbar,b Vanessa Pierroz,a,c
Sandro Konatschnig,a Bernhard Spingler,a Stefano Ferrari,c Robin B. Gasser*b and
Gilles Gasser*‡a
In this study, we present the design, synthesis, characterization and biological evaluation of structurally
new ferrocenyl and ruthenocenyl derivatives of the organic anthelmintic monepantel (Zolvix®). All seven
metallocenyl derivatives prepared (4a/b, 5a/b, 6a/b and 7) were isolated as racemates and characterized
by 1H, 13C and 19F NMR spectroscopies, mass spectrometry, IR spectroscopy and elemental microanalysis.
The molecular structures of four compounds (4a/b, 6a and 7) were further conﬁrmed by X-ray crystallo-
graphy. The biological activities of the organometallic intermediates (4a/b) and organometallic deriva-
tives of monepantel (5a/b, 6a/b and 7) were evaluated in vitro using parasitic nematodes of major impor-
tance in livestock, namely Haemonchus contortus and Trichostrongylus colubriformis. Two ferrocenyl
compounds (4a and 6a) showed nematocidal activity, while the analogous ruthenocenyl compounds (4b
and 6b) were not active at the highest concentration tested (10 μg mL−1). In order to obtain insight into
the diﬀerence in activity between ferrocenyl and ruthenocenyl derivatives, the potential of the com-
pounds for reactive oxidative species (ROS) production in live cells was assessed. Interestingly, neither the
ferrocenyl nor the ruthenocenyl compounds (4a/b and 6a/b) produced signiﬁcant ROS in HeLa cells
when checked after 22 h, potentially indicating a redox-independent activity of 4a and 6a on the para-
sites. The selectivity of the compounds on parasites was conﬁrmed by investigating their cytotoxicity
proﬁles. None of these compounds was toxic either to HeLa or MRC-5 cells. Thus, 4a and 6a could be
considered as interesting leads for further development of new classes of anti-parasitic agents.
Introduction
The impact of parasitic diseases on animals and humans is
substantial around the world. Controlling parasites of domesti-
cated animals is a major issue, and usually relies exclusively
on chemotherapy with an arsenal of broad-spectrum anthel-
mintics.2,3 The excessive use of these drugs has resulted in
the emergence of resistance, and multi-drug resistant
parasites are now widespread.5–8 Apart from the classical
groups of anthelmintics, such as the benzimidazoles, imid-
azothiazoles and macrocyclic lactones, a new synthetic anthel-
mintic class, the amino-acetonitrile derivatives (AADs, see
Scheme 1), has been discovered, and a promising candidate of
this class, called monepantel (AAD 1566), was recently
commercialized.1,9,10
Investigations have shown that the safety profile of mone-
pantel relates to its target, a nematode specific nicotinic acetyl-
choline receptor (nAChr) subunit, which is absent in host
mammals.11–13 Although monepantel now represents a new
class of anthelmintic drug, unfortunately, some years after its
introduction and use in the field, nematodes with reduced
sensitivity to monepantel have been detected in several
countries including Uruguay, New Zealand and Brazil.14–18
Given this rapid emergence of resistance to monepantel, there
is an urgent need to develop novel and superior control strat-
egies to ensure the sustainability of parasite control. With this
in mind, our group recently started to derivatize monepantel
†Electronic supplementary information (ESI) available: 1H, 13C and 19F NMR
spectra (4a/b, 5a/b, 6a/b and 7) (Fig. S1–S16), ORTEP plot of 7 (Fig. S17), anti-
parasitic activity against C. felis, L. cuprina and R. sanguineus of organometallic
precursors and derivatives (4a/b, 5a/b, 6a/b and 7) (Table S1). CCDC
1501422–1501425. For ESI and crystallographic data in CIF or other electronic
format see DOI: 10.1039/c6dt03376h
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with various organometallic moieties using diﬀerent strategies
(Scheme 1).19,20 The derivatization of a known organic drug
with organometallic moieties has proven to be extremely suc-
cessful in various fields of medicinal chemistry.21–35
Ferroquine, a ferrocenyl analogue of the antimalarial drug
chloroquine, is one of the best examples of such a deriva-
tization. Thanks to the presence of a ferrocenyl moiety,
Ferroquine is active against chloroquine-resistant strains of
the malaria parasite, Plasmodium falciparum (P. falciparum),
where the original organic drug chloroquine is inactive.29,36,37
In our initial study, we replaced the aryloxy unit of mone-
pantel with organometallic moieties and modified the benz-
amide part with various functional groups (Scheme 1, Strategy
I/II).19 Subsequently, we replaced the chiral C2 spacer of mone-
pantel by a ferrocenyl moiety that comprised planar chirality
with a 1,2-unsymmetric substitution on a cyclopentadienyl
ring (Scheme 1, Strategy III).20
Extending this work to develop organometallic monepantel
derivatives, we report here a new strategy for achieving structu-
rally distinct organometallic-containing monepantel deriva-
tives. First, we kept the aryloxy unit of monepantel un-
perturbed and substituted the benzamide unit with metallo-
cenes, namely ferrocene and ruthenocene (Scheme 1, Strategy
IV). Then, we replaced simultaneously both the aryloxy and the
benzamide units using two metallocenyl fragments (Scheme 1,
Strategy IV). During the course of present study, we first pre-
pared ferrocenyl monepantel derivatives, since the presence of
the ferrocenyl unit might result in additional metal-specific
modes of action, such as the production of ROS under physio-
logical conditions. In order to investigate if these redox reac-
tions contribute to the antiparasitic activity of our novel
organometallic compounds, we designed ruthenocenyl ana-
logous of the ferrocenyl monepantel derivatives. The replace-
ment of the iron(II) by a ruthenium(II) center is expected to
prevent redox mediated ROS production under physiologically
relevant conditions.36,37
Results and discussion
Synthesis and characterization
The ferrocenyl and ruthenocenyl analogues of monepantel
corresponding to Strategy IV were prepared in a two-step
reaction procedure as presented in Scheme 2. In order to
obtain initial insights into their potential as anthelmintic
agents, we focused on the isolation of the organometallic
derivatives as racemates rather than as their enantiomerically
pure forms.
The syntheses of desired organometallic analogues com-
menced with the preparation of a 2-amino-2-hydroxymethyl-
proprionitrile (1) synthon, following a literature procedure by
Gauvry et al.38 The intermediate N-(2-cyano-1-hydroxypropan-2-yl)-
ferroceneamide (4a) was obtained in a moderate yield by react-
ing 1 with activated ferrocencarboxylic acid (2) under
basic conditions. Moreover, the same reaction allowed the iso-
lation of a di-ferrocenyl analogue of monepantel, 2-ferrocene-
amido-2-cyanopropyl ferroceneoate (5a), with 11% yield.
Compound 4a was then converted to the desired final com-
pound N-(2-cyano-1-(5-cyano-2-(trifluoromethyl)phenoxy)propan-
2-yl)ferroceneamide (6a) using a Williamson ether synthesis
in the presence of NaH and commercially available 3-fluoro-
4-(trifluoromethyl)benzonitrile. Compound 6a was isolated
in 26% yield. In addition to the di-ferrocenyl analogue
5a, another disubstituted organometallic analogue, namely
Scheme 1 Schematic representation of previously (green) and newly
(red) designed organometallic derivatives of monepantel (AAD 1566)
using diﬀerent strategies. OM = ferrocene, ruthenocene or cymantrene;
FG = SCF3, F, Cl, Br, I, SCH3, CF3, OCF3, S(O)CF3, S(O)2CF3.
Scheme 2 Reagents and conditions: (i) (a) oxalyl chloride, dry CH2Cl2,
r.t.; (b) 2-amino-2-hydroxymethylproprionitrile (1), NEt3, dry THF, r.t.,
o.n., 4a (50%), 4b (31%), 5a (11%), 5b (19%); (ii) NaH, 3-ﬂuoro-4-(triﬂuoro-
methyl)benzonitrile, dry THF, overnight, 0 °C→r.t., 6a (26%), 6b (11%); (iii)
(ferrocenylmethyl)trimethylammonium iodide, K2CO3, 18-crown-6, dry
CH3CN, reﬂux, 144 h (120 h plus overnight), 7 (43%).
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N-(1-(ferrocenyloxy)-2-cyanopropan-2-yl)ferroceneamide (7) was
also prepared by reacting 4a with (ferrocenylmethyl)trimethyl-
ammonium iodide under basic conditions. By contrast to
5a, where one of the ferrocenyl units is linked to C2 spacer
by an ester functionality, the similar ferrocene unit in 7 is
attached to the C2 spacer by an ether functionality. Moreover,
we synthesized three ruthenocenyl analogues (4b, 5b and 6b),
which are structurally identical to the ferrocenyl analogues 4a,
5a and 6a. Despite iso-structural, ferrocene and ruthenocene
have distinct redox properties, therefore comparison of the
biological activity of ferrocenyl and the corresponding ruthe-
nocenyl analogues might shed light on the possible involve-
ment of the redox properties in their activity. The synthetic
sequences to obtain the desired ruthenocenyl analogues of
monepantel are similar to those of ferrocenyl compounds (see
Scheme 2). All novel ferrocenyl and ruthenocenyl analogues of
monepantel described here were isolated as racemic mixtures
and characterized by 1H, 13C, 19F NMR spectroscopies, ESI-
mass spectrometry and IR spectroscopy, and their purities
were analyzed by elemental microanalysis.
X-ray crystallography
The molecular structures of four compounds (4a/b, 6a and 7)
were further confirmed by X-ray crystallography. Details of the
crystallization procedure were given in the Experimental
section. The amide unit is coplanar with the cyclopentadienyl
ring. The alcohol of compound 4a is part of a cyclic and a
linear hydrogen-bridge network. The R2
2 (14) cycle39 is formed
by an alcohol hydrogen, making contact with a symmetry (−x,
1 − y, −z)-related carbonyl oxygen; the corresponding alcohol
donates back to the original carbonyl oxygen. Additionally, the
same alcohol is an acceptor of a hydrogen bridge from a sym-
metry related amide nitrogen (−x, 1/2 + y, 1/2 − z). The struc-
tures of 4a and 4b are essentially isostructural, with the major
diﬀerence being that the Fe–C bond lengths in 4a are between
2.0293(14) Å and 2.0619(17) Å, whereas the Ru–C bond lengths
in 4b are between 2.155(3) Å and 2.192(3) Å (see Fig. 1).
Compound 6a does not form any “typical” hydrogen bonds,
despite the presence of an amide unit (see Fig. 1).
Compound 7 was measured on a synchrotron; it crystallized
with two molecules in the asymmetric unit. All cyclopenta-
dienyl rings of the 4 ferrocene units are in an almost perfect
eclipsed conformation. One linker starting from the quartern-
ary carbon to the methylene unit next to the cyclopentadienyl
ring is disordered in a ratio 3 : 2 (see ESI† for structure).
Biological evaluation
The anthelmintic potentials of our ferrocenyl and ruthenoce-
nyl precursors (4a/b) and final derivatives 5a/b, 6a/b and 7
were first evaluated on two common parasites of small rumi-
nants, Haemonchus contortus (H. contortus) and
Trichostrongylus colubriformis (T. colubriformis) using a larval
development assay (LDA) (see Experimental section for
details). The results are summarized in Table 1. The organic
derivatives AAD85, AAD96 and ivermectin were included as
controls.1
Two of seven metal-based monepantel derivatives tested
displayed moderate activities against H. contortus and
T. colubriformis. The final ferrocenyl derivative of Strategy IV
(6a) and its corresponding ferrocene precursor (4a) showed
EC60 values in a similar range when tested against H. contortus
4.90 μg mL−1 (15.70 μM) (4a) and 4.70 μg mL−1 (9.77 μM) (6a)
and T. colubriformis 8.00 μg mL−1 (25.63 μM) (4a) and 7.00 μg
mL−1 (14.55 μM) (6a). Interestingly, the potencies of both
active derivatives (4a, 6a) are approximately twice higher
against H. contortus compared with T. colubriformis. However,
the potencies of 4a and 6a are lower when compared with the
organic controls AAD85 and AAD96, which displayed EC100
values of 0.01 μg mL−1 (0.022 μM/0.021 μM) and 0.032 μg mL−1
(0.07 μM/0.068 μM) against H. contortus and T. colubriformis,
respectively.1 Importantly, the ruthenocenyl analogues (4b, 5b)
of the active ferrocenyl derivatives 4a, 5a displayed no activity
against H. contortus and T. colubriformis at the highest concen-
tration evaluated (10 µg mL−1). At this point, it is reasonable to
speculate that the iron(II) center in 4a and 6a contributes to
the production of toxic ROS which could be the reason for the
observed anti-parasitic activity of these compounds. Therefore,
we evaluated ROS generation using the ferrocene and rutheno-
cene-containing derivatives in live cells (Fig. 2). Although an
assessment of ROS generation in the parasitic nematodes
would have been the ideal, however for technical reasons we
used a mammalian cervical cancer cell line (HeLa) as model.
Fig. 1 Molecular structures of 4a, 4b and 6a with atoms shown as thermal ellipsoids (drawn at 50% probability; hydrogen atoms are omitted for
clarity).
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The ROS production in the cells treated with 4a/b and 6a/b
(25 µM for 22 h) was quantified using the fluorescent indicator
2′,7′-dichlorofluorescein diacetate (H2DCFDA). As positive
control, tert-butyl hydroperoxide (TBH) was included in the
same assay. Surprisingly, as shown in Fig. 1, the ROS levels in
cells treated with the ferrocenyl compounds (4a, 6a) and the
ruthenocenyl compounds (4b, 6b) did not display a significant
diﬀerence. Moreover, the ROS levels of the cells treated with
compounds are comparable to that of the untreated cells.19
The results from ROS assay suggest that the diﬀerences in
anti-parasitic activity between the ferrocene- and ruthenocene-
containing organometallic compounds are not related to the
production of ROS in cells. However, it has to be pointed out
that this is for a timepoint only and that increase in ROS pro-
duction can be faster or can take longer. The potency of the
organometallic monepantel derivatives synthesized using
Strategy IV against H. contortus and T. colubriformis is lower
than for the organometallic derivatives from Strategy I/II (best
EC60 of 1.80 μg mL−1), but superior to those from Strategy III
(best EC60 of 6.60 μg mL−1).19,20 Overall, based on knowledge
obtained from these structure–activity relationships of organo-
metallic monepantel derivatives, it can be concluded that it is
preferable to keep the benzamide part of monepantel un-
perturbed, while structural modifications can be made to the
aryloxy portion for the designing of new derivatives of mone-
pantel to retain anti-parasitic activity against H. contortus and
T. colubriformis.
Previous studies have shown that organometallic derivatiza-
tion modulates the spectrum of activity of a known organic
drug through the addition of metal-specific mode of
actions.37,40 Therefore, we decided to evaluate these com-
pounds further against other parasites.41,42 The activity of our
organometallic-analogues (4a/b, 5a/b, 6a/b and 7) of mone-
pantel was evaluated on the canine heartworm, Dirofilaria
immitis (D. immitis). Two ruthenocenyl compounds (5b, 6b)
showed moderate activity against microfilariae of this nema-
tode species in a 48 h motility assay with EC50 values of
6.60 μg mL−1 (10.74 μM (5b), 12.54 μM (6b)). Interestingly, the
corresponding ferrocenyl derivatives 5a and 6a are inactive
against D. immitis. However, once again, 5b and 6b are less
potent compared to the organic control AAD85, which displays
Table 1 Antiparasitic activity against Haemonchus contortus, Trichostrongylus colubriformis and Diroﬁlaria immitis and cytotoxicity against HeLa
and MRC-5 cells of 4a/b, 5a/b, 6a/b, 7
Compound
EC60 value EC50 value IC50 value
H. contortus T. colubriformis
D. immitis D. immitis
HeLa MRC-5
24 hours 48 hours
[μg mL−1] [μM] [μg mL−1] [μM] [μg mL−1] [μM] [μg mL−1] [μM] [μM] [μM]
4a 4.90 15.70 8.00 25.63 >10.00 >32.04 >10.00 >32.04 >100 >100
5a >10.00 >19.08 >10.00 >19.08 >10.00 >19.08 >10.00 >19.08 >100 >100
6a 4.70 9.77 7.00 14.55 >10.00 >20.78 >10.00 >20.78 >100 >100
4b >10.00 >27.98 >10.00 >27.98 >10.00 >27.98 >10.00 >27.98 >100 >100
5b >10.00 >16.27 >10.00 >16.27 >10.00 >16.27 6.60 10.74 >100 >100
6b >10.00 >18.99 >10.00 >18.99 6.60 12.54 6.60 12.54 >100 >100
7 >10.00 >19.60 >10.00 >19.60 >10.00 >19.60 >10.00 >19.60 >100 >100
0.01a 0.022a 0.032a 0.07a 2.40 5.25 2.20 4.81 n.d. n.d.
0.01a 0.021a 0.032a 0.068a n.d.i. n.d.i. n.d.i. n.d.i. n.d. n.d.
Ivermectine 0.001a 0.001a 0.01a 0.011a 1.00–3.00 1.14–3.43 1.00–3.00 1.14–3.43 n.d. n.d.
Cisplatin n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 9.6 ± 1.2 17.6 ± 4.3
a EC100 value
1. n.d.i. = non-disclosable information4 and n.d. = not determined. EC values are given in μg mL−1 as well as in μM. EC values are
calculated as a mean of 2 series of triplicated dose responses. Experimental errors are not included as they are too low to influence the overall
EC values.
Fig. 2 Level of ROS production in HeLa cells untreated or treated with
4a, 4b, 6a and 6b after 22 h. THB = tert-butyl hydroperoxide.
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an EC50 value of 2.20 μg mL−1 (4.81 μM).4 In addition to this,
we further investigated the activity of the ferrocenyl and ruthe-
nocenyl precursors (4a/b) and final derivatives 5a/b, 6a/b and 7
on three arthropods Ctenocephalides felis (cat flea), Lucilia
cuprina (blow fly) and Rhipicephalus sanguineus (brown dog
tick). Unfortunately, none of the compounds synthesized dis-
played potency at the highest concentration tested on C. felis
(100 μg mL−1), L. cuprina (32 μg mL−1) or R. sanguineus
(100 μg mL−1 and 640 μg mL−1) (Table S1†).
For development of new anti-parasitic compounds, the
selectivity of the compounds towards parasites is an important
parameter. An ideal anthelmintic should be non-toxic to the
mammalian host, while being eﬃcient in killing the parasites.
For this purpose, we evaluated the cytotoxicity of the com-
pounds using a cervical cancer cell line (HeLa) and a non-
cancerous human lung fibroblast cell line (MRC-5). None of
the compounds tested were toxic up to 100 µM (the highest
concentration assayed), indicating selectivity of our com-
pounds (4a, 6a) to the nematodes H. contortus, T. colubriformis
and D. immitis over mammalian cells.
Conclusion
The extensive use of commercially available broad-spectrum
organic anthelmintics has led to a situation where parasites
develop resistant to at least one or more available drug classes.
With the view of developing a new class of metal-based anthel-
mintic agents, we synthesized and characterized a series of
ferrocene- and ruthenocene-containing organometallic ana-
logues of the anthelmintic drug monepantel. The biological
eﬃcacy of all newly synthesized intermediates as well as final
analogues (4a/b, 5a/b, 6a/b, 7) was assessed in a LDA against
H. contortus and T. colubriformis. Two ferrocenyl derivatives 4a
and 6a showed moderate eﬃcacy with EC60 values between
4.70–8.00 μg mL−1 against both nematode species, while the
corresponding ruthenocenyl derivatives displayed no activity.
The ROS production of both types of organometallic deriva-
tives (4a/b and 6a/b) was evaluated in an in vitro model using
the HeLa cervical cancer cell line. However, no significant
diﬀerence in ROS levels after 22 h was observed between the
ferrocenyl (4a and 6a) and ruthenocenyl (4b and 6b) ana-
logues. This unexpected finding might suggest a redox inde-
pendent mode of action for the anti-parasitic activity of the
ferrocenyl derivatives (4a and 6a) although more investigations
will need to be performed to confirm this hypothesis. The
selectivity of the compounds towards parasites was demon-
strated by assessment of their cytotoxicity using a cancer
(HeLa) and a non-cancer (MRC-5) cell line.
Experimental section
Materials
All chemicals were of reagent grade quality or better, obtained
from commercial suppliers and used without further purifi-
cation. Solvents were used as received or distilled using stan-
dard procedures.43 All preparations were carried out using
standard Schlenk techniques. Thin layer chromatography
(TLC) was performed using silica gel 60 F-254 (Merck) plates
with detection of spots being achieved by exposure to UV light.
Column chromatography was performed using Silica gel 60
(0.040–0.063 mm mesh, Merck). Eluent mixtures are expressed
as volume to volume (v/v) ratios. Chlorocarbonyl ferrocene and
chlorocarbonyl ruthenocene were synthesized according to lit-
erature procedures.44
Instrumentation and methods
1H, 13C and 19F NMR spectra were recorded in deuterated sol-
vents on Bruker 400 or 500 MHz NMR at room temperature.
The chemical shifts, δ, are reported in ppm (parts per
million). The signals from the residual protons of deuterated
solvent have been used as an internal reference.45,46 The
abbreviations for the peak multiplicities are as follows: s
(singlet), d (doublet), dd (doublet of doublets), t (triplet), q
(quartet), m (multiplet), and br (broad). ESI mass spectrometry
was performed using a Bruker Esquire 6000 spectrometer. In
the assignment of the mass spectra, the most intense peak is
listed. UPLC-ESI-MS was performed on a Waters Acquity UPLC
System coupled to a Bruker HCTTM, using an Acquity UPLC
BEH C18 1.7 μm (2.1 × 50 mm) as a reverse phase column with
a flow rate of 0.6 mL min−1. The UV absorption was measured
at 254 nm. The runs were performed with a linear gradient of
A (acetonitrile (Sigma-Aldrich HPLC grade) and B (distilled
water containing 0.02% TFA and 0.05% HCOOC)): t =
0–0.5 min, 5% A; t = 4.0 min, 100% A; t = 5 min, 100%
A. High-resolution mass spectrometry were performed on a
Bruker ESQUIRE-LC quadrupole ion trap instrument (Bruker
Daltonik GmbH, Bremen, Germany), equipped with a com-
bined Hewlett-Packard Atmospheric Pressure Ion (API) source
(Hewlett-Packard Co., Palo Alto, CA, USA). The solutions
(about 0.1–1 µmol ml−1) were continuously introduced
through the electrospray interface with a syringe infusion
pump (Cole-Parmer 74900-05, Cole-Parmer Instrument
Company, Vernon Hills, Illinois, USA) at a flow rate of
5 µl min−1. The MS-conditions were: nebulizer gas (N2) 15 psi,
dry gas (N2) 7 min
−1, dry temperature 300 °C, capillary voltage
4000 V, end plate 3500 V, capillary exit 100 V, skimmer1 30 V,
and trap drive 70. The MS acquisitions were performed at
normal resolution (0.6 u at half peak height), under ion charge
control (ICC) conditions (10 000) in the mass range from m/z
100 to 2000. To get representative mass spectra, 8 scans were
averaged. Infrared spectra were recorded on Perkin-Elmer FTIR
spectrometer using KBr pellets. Peak intensities are given as
broad (b), very strong (vs), strong (s), medium (m) and weak
(w). Elemental microanalyses were performed on a
LecoCHNS-932 elemental analyser.
Synthesis
N-(2-Cyano-1-hydroxypropan-2-yl)ferroceneamide (4a) and
2-ferroceneamido-2-cyanopropyl ferroceneoate (5a).
Chlorocarbonyl ferrocene (0.648 g, 2.608 mmol) and 2-amino-
Paper Dalton Transactions
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2-hydroxymethylproprionitrile (0.261 g, 2.608 mmol) were dis-
solved in dry THF (100 mL). To this orange reaction solution,
NEt3 (453 μL, 3.26 mmol) was added and the mixture was
stirred overnight at room temperature. The solvent was evapor-
ated under reduced pressure. The crude residue was dissolved
in CH2Cl2 (30 mL), washed with H2O (2 × 10 mL) and brine
(2 × 10 mL). The organic layer was dried over MgSO4, filtered and
the solvent was evaporated under reduced pressure. The crude
product was purified by column chromatography on silica with
hexane : ethyl acetate (4 : 1) as eluent (Rf (5a) = 0.69, hexane :
ethyl acetate 1 : 1, Rf (4a) = 0.30, hexane : ethyl acetate 1 : 1) to
aﬀord 2-ferroceneamido-2-cyanopropyl ferroceneoate (5a) and
N-(2-cyano-1-hydroxypropan-2-yl)ferroceneamide (4a) as orange
solids, respectively. Yield: 11% (5a, 0.075 g, 0.143 mmol) and
50% (4a, 0.41 g, 1.31 mmol). Data 4a: IR (KBr, cm−1): 3467s,
3412s, 3103w, 2941w, 2862w, 1635s, 1534m, 1454w, 1377w,
1312m, 1267w, 1201w, 1160w, 1099w, 1056m, 1037w, 1023w,
998w, 911w, 826w, 772w, 710w, 620m, 528w, 499w, 483w,
464w. 1H NMR (400 MHz, d6-acetone): δ/ppm = 7.12 (s, 1H,
NH), 5.01 (t, 3J = 6.4 Hz, 1H, OH), 4.85–4.84 (m, 2H, C5H4),
4.39–4.38 (m, 2H, C5H4), 4.24 (s, 5H, C5H5), 4.0–3.93 (m, 1H,
CH2), 3.90–3.86 (m, 1H, CH2), 1.71 (s, 3H, CH3).
13C NMR
(125 MHz, d6-acetone): δ/ppm = 170.9, 121.1, 76.1, 71.5, 70.5,
69.5, 69.4, 67.0, 66.9, 53.3, 22.6. ESI-MS: m/z (%) = 351.02 [M +
K]+ (8), 335.04 [M + Na]+ (100), 312.06 [M]+ (52). HR ESI-MS:
m/z (%) = 312.05557, calcd for C15H16FeN2O2 (M
+) m/z (%) =
312.05508. Elemental analysis: calcd for C15H16N2O2Fe = C,
57.72; H, 5.17; N, 8.97. Found = C, 57.48; H, 5.13; N, 8.69. Data
5a: IR (golden gate, cm−1): 3368w, 1690m, 1656m, 1520m,
1453w, 1378w, 1288m, 1264w, 1214w, 1164m, 1144m, 1104w,
1027w, 999w, 918w, 827m, 814m, 770m, 741w. 1H NMR
(500 MHz, d6-acetone): δ/ppm = 7.53 (s, 1H, NH), 4.88–4.87 (m,
4H, C5H4), 4.77 (d,
2J = 10.8 Hz, 1H, CH2), 4.82–4.50 (m, 3H,
C5H4, CH2), 4.44–4.41 (m, 2H, C5H4), 4.27 (s, 5H, C5H5), 4.25
(s, 5H, C5H5), 1.90 (s, 3H, CH3).
13C NMR (125 MHz, d6-
acetone): δ/ppm = 171.7, 170.7, 120.21, 75.8, 72.7, 71.7, 71.0,
70.8, 70.6, 69.5, 69.4, 66.9, 51.5, 23.1. ESI-MS: m/z (%) = 524.1
[M]+ (100). Elemental analysis: calcd for C26H24N2O3Fe2 = C
59.58; H 4.62; N 5.34. Found = C 59.51; H 4.52; N 5.25.
N-(2-Cyano-1-hydroxypropan-2-yl)ruthenoceneamide (4b)
and 2-cyano-2-(ruthenocenecarboxamido)propyl ruthenocne-
carboxylate (5b). Chlorocarbonyl ruthenocene (1.67 g,
6.96 mmol) and 2-amino-2-hydroxymethylproprionitrile
(1.05 g, 10.5 mmol) were dissolved in dry THF (50 mL). To this
colourless reaction solution NEt3 (6.8 mL, 50 mmol) was
added and the mixture was stirred overnight at room tempera-
ture. The solvent was evaporated under reduced pressure. The
crude product was purified by column chromatography on
silica with hexane : ethyl acetate 7 : 1 → 1 : 7, and the methanol
as eluent (Rf (4b) = 0.05, hexane : ethyl acetate 7 : 1, Rf (5b) =
0.2, methanol) to aﬀord N-(2-cyano-1-hydroxypropan-2-yl)
ruthenocenamide (4b) and 2-cyano-2-(ruthenocenecarboxa-
mido)propyl ruthenocnecarboxylate (5b) as pale yellow solids,
respectively. Yield: 31% (4b, 0.77 g, 2.06 mmol) and 19% (5b,
0.81 g, 1.32 mmol). Data 4b: IR (KBr, cm−1): 3248br, 31122s,
3056w, 2943w, 2887w, 2641w, 2324w, 2241w, 2050w, 1981w,
1720w, 1633s, 1531s, 1455s, 1376s, 1308s, 1130s, 823s. 1H
NMR (500 MHz, DMSO): δ/ppm = 7.51 (s, 1H, NH), 5.64 (t, 3J =
6.46 Hz, 1H, OH), 5.23–5.22 (m, 2H, C5H4), 4.73–4.73 (m, 2H,
C5H4), 4.59 (s, 5H, C5H5), 3.80–3.76 (m, 1H, CH2), 3.53–3.50
(m, CH2), 1.54 (s, 3H, CH3).
13C NMR (125 MHZ, DMSO): δ/
ppm = 168.1, 120.5, 79.1, 72.4, 72.3, 71.6, 70.4, 70.3, 64.8, 51.9,
21.7. ESI-MS: m/z (%) = 359.1 [M + H]+ (100), 259.0 [M −
C4H4N2OH]
+ (17). Elemental Analysis: calcd for C15H16O2N2Ru
= C, 50.41; H, 4.51; N, 7.84. Found = C, 50.85; H, 4.44; N, 7.41.
Data 5b: IR (KBr, cm−1): 3320m, 3104w, 2956w, 2651w, 2322w,
2161s, 2053s, 1976s, 1690s, 1656s, 1521s, 1450s, 1373s, 1267s,
1135s, 1035m, 997m, 808s, 759m. 1H NMR (500 MHz, DMSO):
δ/ppm = 7.93 (s, 1H, NH), 5.27–5.25 (m, 2H, C5H3), 5.15–5.13
(m, 2H, C5H3), 4.85–4.84 (m, 2H, C5H4), 4.76–4.75 (m, 2H,
C5H4), 4.65 (s, 5H, C5H3), 4.59 (s, 5H, C5H3), 4.51 (d,
2J = 10.8,
2H, CH2), 4.27 (d,
2J = 10.4, 2H, CH2), 1.66 (s, 3H, CH3).
13C
NMR (125 MHZ, DMSO): δ/ppm = 168.6, 168.2, 119.2, 78.7,
74.1, 73.3, 72.5, 71.9, 71.6, 71.4, 70.5, 70.3, 64.9, 49.7, 22.1.
ESI-MS: m/z (%) = 639.3 [M + Na]+ (100). Elemental analysis:
calcd for C26H24O3N2Ru2 = C 50.81; H 3.94; N 4.56. Found = C
50.92; H 3.96; N 4.53.
N-(2-Cyano-1-(5-cyano-2-(trifluoromethyl)phenoxy)propan-2-
yl)ferroceneamide (6a). N-(2-Cyano-1-hydroxypropan-2-yl)ferro-
ceneamide (4a, 0.020 g, 0.064 mmol) was dissolved in dry THF
(30 mL). The orange solution was cooled to 0 °C and NaH
(0.0018 g, 0.074 mmol) was added. After stirring the reaction
mixture for 30 min at 0 °C 3-fluoro-4-(trifluoromethyl)benzo-
nitrile (0.012 g, 0.064 mmol) was added. After stirring the reac-
tion mixture overnight at room temperature, additional NaH
(0.0018 g, 0.074 mmol) and 3-fluoro-4-(trifluoromethyl)benzo-
nitrile (0.012 g, 0.064 mmol) were added to the reaction
mixture. Another portion of NaH (0.0018 g, 0.074 mmol) was
added 2 h later. The reaction was quenched with H2O (2 mL)
and brine (6 mL) and the aqueous layer was extracted with
ethyl acetate (3 × 10 mL). The combined organic layers were
dried over MgSO4, filtered and the solvent was evaporated
under reduced pressure. The crude product was purified by
column chromatography on silica with hexane : ethyl acetate
(6 : 1) as the eluent (Rf = 0.36, hexane : ethyl acetate 2 : 1) to
give N-(2-cyano-1-(5-cyano-2-(trifluoromethyl)phenoxy)propan-
2-yl)ferroceneamide (6a) as an orange solid. Yield: 26%
(0.041 g, 0.085 mmol). IR (KBr, cm−1): 3478s, 3414s, 3355s,
2925s, 2851m, 2358m, 2336m, 2240s, 1653s, 1613s, 1574w,
1527m, 1510w, 1465m, 1415m, 1409w, 1373w, 1309m, 1281m,
1261w, 1211w, 1180m, 1141m, 1131m, 1037m, 895w, 841w,
822w, 632w, 606w, 531w, 503w, 486w. 1H NMR (400 MHz, d6-
acetone): δ/ppm = 7.90 (d, 3J = 8.4 Hz, 1H, arom.), 7.84 (s, 1H,
arom.), 7.61 (d, 3J = 7.6 Hz, 1H, arom.), 7.52 (s, 1H, NH),
4.88–4.83 (m, 2H, C5H4; 1H, CH2), 4.67 (d,
2J = 9.2 Hz, 1H,
CH2), 4.41–4.40 (m, 2H, C5H4), 4.22 (s, 5H, C5H5), 1.93 (s, 3H,
CH3).
13C NMR (125 MHz, d6-acetone): δ/ppm = 170.9, 157.0,
129.3, 129.2, 129.2, 129.1, 126.0, 125.1, 123.2, 123.0, 122.9,
119.7, 118.4, 118.0, 75.6, 71.9, 71.7, 71.6, 70.6, 69.6, 69.4, 51.2,
23.0. 19F NMR (282.23 MHz, d6-acetone): δ/ppm = −63.6.
ESI-MS: m/z (%) = 504.0 [M + Na]+ (100), 985.1 [2M + Na]+ (12).
HR ESI-MS: m/z (%) = 504.05927 calcd for C23H18F3FeN3NaO2
Dalton Transactions Paper
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([M + Na]+) m/z (%) = 504.05958. Elemental analysis: calcd for
C23H18N3O2F3Fe = C 57.40; H 3.77; N 8.73. Found = C 57.62; H
4.01; N 8.38.
N-(2-Cyano-1-(5-cyano-2-(trifluoromethyl)phenoxy)propan-2-
yl)ruthenoceneamide (6b). N-(2-Cyano-1-hydroxypropan-2-yl)
ruthenocenamide (4b, 0.150 g, 0.42 mmol) was dissolved in
dry THF (30 mL). The colorless solution was cooled to 0 °C
and NaH (0.015 g, 0.63 mmol) was added. After stirring the
reaction mixture for 30 min at 0 °C 3-fluoro-4-(trifluoromethyl)
benzonitrile (0.080 g, 0.42 mmol) was added. After stirring the
reaction mixture overnight at room temperature, additional
NaH (0.005 g, 0.21 mmol) and 3-fluoro-4-(trifluoromethyl)
benzonitrile (0.040 g, 0.21 mmol) were added to the reaction
mixture and the reaction was allowed to stir for another 3 h.
The reaction was quenched with H2O (2 mL) and brine (6 mL)
and the aqueous layer was extracted with ethyl acetate (3 ×
10 mL). The combined organic layers were dried over Na2SO4,
filtered and the solvent was evaporated under reduced
pressure. The crude product was purified by column chromato-
graphy on silica with hexane : ethyl acetate 2 : 1 as the eluent
(Rf = 0.60) to give N-(2-cyano-1-(5-cyano-2-(trifluoromethyl)
phenoxy)propan-2-yl)ruthenoceneamide (6b) as white solid.
Yield: 11% (0.024 g, 0.046 mmol). IR (KBr, cm−1): 3341br,
3076br, 2952w, 2234s, 2165w, 1977s, 1630s, 1575s, 1528s,
1416s, 1285s, 1264s, 1186s, 1132s, 1039s, 816s, 815s, 735s. 1H
NMR (500 MHz, d6-acetone): δ/ppm = 7.89 (d, 3J = 8.0 Hz, 1H,
arom. H), 7.80 (s, 1H, arom. H), 7.61 (d, 3J = 8.0 Hz, 1H, arom.
H), 7.34 (s, 1H, NH), 5.20–5.19 (m, 2H, C5H4), 4.77 (d,
3J = 9.5
Hz, 1H, CH2), 4.71 (s, 2H, C5H4), 4.60–4.58 (m, 6H, CH2 and
C5H5), 1.87 (s, 3H, CH3).
13C NMR (125 MHZ, d6-acetone):
δ/ppm = 169.6, 169.5, 157.0, 156.9, 129.3, 129.3, 129.2, 129.2,
127.2, 126.1, 125.1, 123.5, 123.3, 123.0, 122.9, 122.8, 120.7,
119.6, 118.4, 118.4, 118.1, 118.0, 79.9, 79.9, 73.2, 73.2, 72.5,
72.0, 72.0, 71.2, 71.1, 51.2, 51.1, 22.9, 22.9. 19F NMR
(470.59 MHz, d6-acetone): δ/ppm = −63.4. ESI-MS: m/z (%) =
550.0 [M + Na]+ (100). HR ESI-MS: m/z = 528.04751, calcd for
C23H18F3N3O2Ru ([M]) m/z = 528.04733; m/z (%) = 550.02942,
calcd for C23H18F3N3NaO2Ru ([M + Na]) m/z (%) = 550.02928.
Elemental analysis: calcd for C23H21F3N3O3Ru(H2O) = C 50.73;
H 3.70; N 7.72. Found = C 50.61; H 3.40; N 7.51.
N-(1-(Ferrocenyloxy)-2-cyanopropan-2-yl)ferroceneamide (7).
N-(2-Cyano-1-hydroxypropan-2-yl)ferroceneamide (4a, 0.03 g,
0.096 mmol), (ferrocenylmethyl)trimethylammonium iodide
(0.065 g, 0.17 mmol), K2CO3 (39.8 mg, 0.288 mmol) and
18-crown-6 (0.0076 g, 0.0288 mmol) were dissolved in dry
CH3CN (20 mL) and refluxed (90 °C) for 120 h. Additional
(ferrocenylmethyl)trimethylammonium iodide (0.065 g,
0.17 mmol) was added to the reaction and further refluxed
overnight. The orange reaction mixture was allowed to reach
room temperature. The solvent was evaporated under reduced
pressure. The crude residue was redissolved in Et2O (10 mL)
and washed with H2O (2 × 5 mL) and brine (2 × 5 mL). The
organic phase was dried over MgSO4, filtered and the solvent
was evaporated under reduced pressure. The crude product
was purified by column chromatography on silica using
hexane : ethyl acetate 3 : 1 as the eluent (Rf = 0.29) to aﬀord
N-(1-(ferrocenyloxy)-2-cyanopropan-2-yl)ferroceneamide (7) as a
yellow solid. Yield: 43% (0.021 g, 0.041 mmol). IR (KBr, cm−1):
3469s, 2929w, 2852w, 1637s, 1518s, 1378w, 1339w, 1305w,
1280w, 1101m, 1008m, 825m, 523m, 502m, 485m. 1H NMR
(500 MHz, CD3CN): δ/ppm = 6.48 (s, 1H, NH), 4.73–4.70 (m,
2H, C5H4), 4.46 (s, 2H, RCH2OR), 4.39–4.38 (m, 2H, C5H4),
4.32–4.31 (m, 2H, C5H4), 4.20 (s, 7H, C5H5, C5H4), 4.17 (s, 5H,
C5H5), 3.80 (d,
3J = 9.3 Hz, 1H, CH2), 3.70 (d,
3J = 9.3 Hz, 1H,
CH2), 1.68 (s, 3H, CH3).
13C NMR (125 MHz, CD3CN): δ/ppm =
207.9, 171.2, 121.2, 83.9, 75.6, 73.5, 71.9, 70.7, 70.6, 70.5, 69.6,
69.5, 69.5, 69.4, 51.7, 22.9. ESI-MS: m/z (%) = 484.03 [M − CN]+
(12), 510.04 [M]+ (100), 533.00 [M + Na]+ (7). HR ESI-MS: m/z
(%) = 510.06882, calcd for C26H26Fe2N2O2 ([M + Na]
+) m/z (%) =
510.06864. Elemental analysis: calcd for C26H26N2O2Fe2 = C
61.21; H 5.14; N 5.49. Found = C 61.06; H 5.20; N 5.31.
Crystallographic studies
Single crystals of 4a and 7 were grown by slow evaporation of
acetonitrile solutions of 4a or 7 respectively. Single crystals of
4b were grown by slow evaporation of an dichloromethane
solution of 4b. Single crystals of 6a were grown by slow evapor-
ation of an acetone solution of 6a.
Crystallographic data of 4a, 4b and 6a were collected at 183
(2) K with Mo Kα radiation (λ = 0.7107 Å) that was graphite-
monochromated on an Oxford Diﬀraction CCD Xcalibur
system with a Ruby detector. Suitable crystals were covered
with oil (Infineum V8512, formerly known as Paratone N),
placed on a nylon loop that is mounted in a CrystalCap
Magnetic™ (Hampton Research) and immediately transferred
to the diﬀractometer. The program suite CrysAlisPro was used
for data collection, multi-scan absorption correction and data
reduction.47 Crystallographic data of 7 were collected at 100(2)
K at the PXIII beamline of the SLS synchrotron with a radiation
wavelength of 0.71255 Å. The data was integrated with the XDS
software48 and further processed with the CCP4 49 and
POINTLESS50 software. The data has a low completeness
because of the one-circle geometry at the beamline and the
low symmetry. All structures were solved with direct methods
using SIR97 51 and were refined by full-matrix least-squares
methods on F2 with SHELXL-2014.52 CCDC entries
1501422–1501425 contain the X-ray data of compounds 4a, 4b,
6a and 7.
Bioassay/s to assess anti-parasitic activity
Some parasites were produced in vivo in or on animals.
Haemonchus contortus and Trichostrongylus colubriformis (stron-
gylid nematodes) were maintained in sheep, and Dirofilaria
immitis (filarial nematodes) in dogs. Rhipicephalus sanguineus
(tick) was maintained on dogs. All animal experiments were
approved by the State of Fribourg, Switzerland, and supervised
by the Animal Welfare Oﬃcer of Novartis Animal Health.
Other parasites, that is, Ctenocephalides felis (flea) and Lucilia
cuprina (fly), were produced in vitro and maintained on defibri-
nated cattle blood. All bioassays were performed by Novartis
Animal Health employing industry-standard operating
procedures.
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Assay to test activity in vitro against Haemonchus contortus
and Trichostrongylus colubriformis
This method was conducted as described by Kaminsky et al.
(2008).10 In brief, freshly harvested and cleaned nematode
eggs were seeded into a 96-well plate containing the test sub-
stances to be evaluated for anthelmintic activity. Each com-
pound was tested by serial dilution in order to determine its
minimum eﬀective dose. The test compounds were embedded
in an agar-based nutritive medium allowing the full develop-
ment of eggs through to third stage larvae (L3). The plates
were incubated for 6 days at 28 °C and 80% relative humidity.
Egg hatching and ensuing larval development were recorded to
identify a possible nematocidal activity. Eﬃcacy was expressed
as a percentage of reduced egg hatch, reduced development of
L3, or paralysis and death of larvae of all stages.
Activity in vitro against Dirofilaria immitis
Microfilariae present in blood from donor dogs chronically
infected with D. immitis were seeded into 96-well microplates.
Individual test compounds were tested by serial dilution to
determine their minimum eﬀective doses. The plates were
incubated for 48 h at 26 °C and 60% relative humidity. The
motility of microfilariae was then recorded to identify any anti-
filarial activity. Eﬃcacy was expressed as the percentage of
reduced motility compared to the control (untreated) and stan-
dards. In these assays, a compound needed to exhibit a nemato-
dicidal eﬃcacy of >60% at a concentration of 32 µg ml−1
(32 ppm) to qualify for further testing.
Activity in vitro against Ctenocephalides felis
Oral test. This test was conducted as described by Wade
et al. (1988) and Zakson-Aiken et al. (2001).53,54 In brief, adult
fleas were placed in a suitably formatted microtitration plate,
allowing fleas to access and feed on treated blood via an artifi-
cial feeding system. Each compound was tested by serial
dilution to determine its minimum eﬀective doses. Fleas were
fed on treated blood for 24 h, after which the compound’s
eﬀect was recorded. Insecticidal activity was determined on
the basis of the number of dead fleas recovered from the
feeding system.
Contact test. This test was conducted as described by Wade
et al. (1988) and Zakson-Aiken et al. (2001).53,54 In brief, adult
fleas were distributed into wells of a microplate pre-coated
with a serial dilution of the compounds to be evaluated for
insecticidal activity. The fleas were left in contact with the
compound for 24 h. Insecticidal activity was confirmed upon
death of the adult fleas. In these assays, a compound needed
to exhibit an insecticidal eﬃcacy of >80% at a concentration of
100 ppm (100 µg ml−1) to qualify for further testing.
Activity in vitro against Rhipicephalus sanguineus (dog tick)
Immersion test. This test was conducted as described by
Lovis et al. (2011).55 In brief, adult Rhipicephalus sanguineus
were seeded into individual wells of a microtitration plate con-
taining the test substances to be evaluated. Individual test
compounds were tested by serial dilution to determine their
minimum eﬀective doses. Ticks were left in contact with the
test compound for 10 min and then incubated at 28 °C and
80% relative humidity for seven days, during which the test
compounds’ eﬀects were monitored. Acaricidal activity was
confirmed based on the pattern of lethality observed.
Contact (tarsal) test. This test was conducted as described
by Lovis et al. (2013).56 In brief, the test was performed by pre-
coating wells of a 96-well microliter plate with a serial dilution
of compound, allowing the evaluation of anti-parasitic activity
by contact with ticks. Adult ticks were then distributed to indi-
vidual wells of the plate and incubated at 28 °C and 80% rela-
tive humidity for seven days, during which the test com-
pound’s eﬀect was monitored. Acaricidal activity was con-
firmed upon death of the adult ticks.
Determination of ROS level
The assay was performed following a procedure published by
our group with slight modification.57 Briefly, HeLa cells (8000
in 100 µL medium per well) were seeded in a 96 well plate
(black, clear flat bottom from corning). Next day, the media
was aspirated and 200 µM fresh media containing 4a, 4b, 6a or
6b (freshly prepared stock solution in DMSO, after dilution
with culture medium final concentration of DMSO ≤0.3%,
25 µM exposure concentration) was added. Cells were then
incubated at 37 °C incubator for 22 h. The medium was then
removed, washed with 150 µL PBS and then 150 µL solution of
H2DCFDA (final concentration 20 μM) in serum free medium
was added and incubated for 40 min in dark. The fluorescence
generated by intracellular ester cleavage followed by oxidation
of H2DCFDA by intracellular ROS was quantified at 528 nm
emission with 485 nm excitation wavelength in a SpectraMax
M5 microplate reader. For the positive control TBH, 100 µM
concentration and 6 h incubation time was used. After quanti-
fication of the ROS, cell viability on HeLa cells was determined
to quantify the potential decrease in cellular mass due to treat-
ment with diﬀerent compounds. The media was aspirated and
cells were washed with 150 µL PBS. Afterwards, 100 µL 0.4%
formaldehyde in PBS was added and cells were allowed to fix
for 20 min at room temperature. The formaldehyde solution
was aspirated and cells were washed with 150 µL PBS. 0.02%
crystal violet (CV) solution in PBS was then added (100 µL per
well) and incubated at room temperature for 30 min. The CV
solution was then aspirated, washed with 150 µL of distilled
water and dried overnight. Next day, 180 µL 80% ethanol was
added to each well and the plates were gently shaken on a
rocker for 2–3 h and were read at 570 nm in a SpectraMax
M5 microplate reader. The results expressed as mean and stan-
dard error of six replicates, corrected for the viable cell
population.
Cell culture
Human cervical carcinoma cells (HeLa) were cultured in
DMEM (Gibco) supplemented with 5% fetal calf serum (FCS,
Gibco), 100 U ml−1 penicillin, 100 μg ml−1 streptomycin at
37 °C and 5% CO2. The normal human fetal lung fibroblast
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MRC-5 cell line was maintained in F-10 medium (Gibco) sup-
plemented with 10% FCS (Gibco), penicillin (100 U ml−1), and
streptomycin (100 μg ml−1).
Cytotoxicity studies
Cytotoxicity studies were performed on two diﬀerent cell lines,
namely HeLa, and MRC-5, by a fluorometric cell viability assay
using Resazurin (Promocell GmbH). Briefly, one day before
treatment, cells were seeded in triplicates in 96-well plates at a
density of 4 × 103 cells per well for HeLa and 7 × 103 for MRC-5
in 100 μl growth medium. Upon treating cells with increasing
concentrations of organometallic-monepantel derivatives for
48 h, the medium was removed, and 100 μl complete medium
containing Resazurin (0.2 mg ml−1 final concentration) were
added. After 4 h of incubation at 37 °C, fluorescence of the
highly red fluorescent product Resorufin was quantified at
590 nm emission with 540 nm excitation wavelength in a
SpectraMax M5 microplate reader.
Abbreviations
AADs Amino-acetonitrile derivatives
C. felis Ctenocephalides felis
D. immitis Dirofilaria immitis
ESI-MS Electrospray ionisation-mass spectrometry
H. contortus Haemonchus contortus
H2DCFDA 2′,7′-Dichlorofluorescein diacetate
LDA Larval development assay
L. cuprina Lucilia cuprina
nAChR Nicotinic acetylcholine receptor
o.n. Overnight
P. falciparum Plasmodium falciparum
ROS Reactive oxygen species
R. sanguineus Rhipicephalus sanguineus
r.t. Room temperature
SAR Structure activity relationship
TBH tert-Butyl hydroperoxide
T. colubriformis Trichostrongylus colubriformis.
Acknowledgements
This work was financially supported by the Swiss National
Science Foundation (Professorships No. PP00P2_133568 and
PP00P2_157545 to G. G.), the University of Zurich (G. G., S. F.),
the Stiftung für wissenschaftliche Forschung of the University
of Zurich (G. G., S. F.), the Novartis Jubilee Foundation (G. G.),
the Kurt u. Senta Hermann Stiftung (S. F.) and the Swiss
Government Excellence Scholarship for Postdoctoral
Researcher (R. L.). R. B. G.’s research program is supported by
the Australian Research Council (ARC), the National Health
and Medical Research Council (NHMRC), Melbourne Water
Corporation, Yourgene Bioscience and the Alexander von
Humboldt Foundation and The University of
Melbourne. R. B. G. is a grateful recipient of Professorial
Humboldt Research Awards. The authors would like to thank
Dr Jacques Bouvier (Novartis Animal Health, St-Aubin,
Switzerland) and Dr Noëlle Gauvry (Novartis Animal Health,
Basel, Switzerland) for their help with the biological assays.
References
1 P. Ducray, N. Gauvry, F. Pautrat, T. Goebel, J. Fruechtel,
Y. Desaules, S. S. Weber, J. Bouvier, T. Wagner, O. Froelich
and R. Kaminsky, Bioorg. Med. Chem. Lett., 2008, 18, 2935–
2938.
2 R. Kaminsky, L. Rufener, J. Bouvier, R. Lizundia,
S. Schorderet Weber and H. Sager, Vet. Parasitol., 2013, 195,
286–291.
3 C. P. Gordon, L. Hizartzidis, M. Tarleton, J. A. Sakoﬀ,
J. Gilbert, B. E. Campbell, R. B. Gasser and A. McCluskey,
MedChemComm, 2014, 5, 159–164.
4 For legal issues the eﬃcacy of AAD96 cannot be disclosed.
5 R. M. Kaplan and A. N. Vidyashankar, Vet. Parasitol., 2012,
186, 70–78.
6 R. M. Kaplan, Trends Parasitol., 2004, 20, 477–481.
7 S. B. Howell, J. M. Burke, J. E. Miller, T. H. Terrill,
E. Valencia, M. J. Williams, L. H. Williamson, A. M. Zajac
and R. M. Kaplan, J. Am. Vet. Med. Assoc., 2008, 233, 1913–
1919.
8 L. L. Mortensen, L. H. Williamson, T. H. Terrill,
R. A. Kircher, M. Larsen and R. M. Kaplan, J. Am. Vet. Med.
Assoc., 2003, 23, 495–500.
9 C. Epe and R. Kaminsky, Trends Parasitol., 2013, 29, 129–134.
10 R. Kaminsky, P. Ducray, M. Jung, R. Clover, L. Rufener,
J. Bouvier, S. S. Weber, A. Wenger, S. Wieland-Berghausen,
T. Goebel, N. Gauvry, F. Pautrat, T. Skripsky, O. Froelich,
C. Komoin-Oka, B. Westlund, A. Sluder and P. Maser,
Nature, 2008, 452, 176–180.
11 L. Rufener, J. Keiser, R. Kaminsky, P. Mäser and
D. Nilsson, PLoS Pathog., 2010, 6, e1001091.
12 R. Baur, R. Beech, E. Sigel and L. Rufener, Mol. Pharmacol.,
2015, 87, 96–102.
13 L. Rufener, N. Bedoni, R. Baur, S. Rey, D. A. Glauser,
J. Bouvier, R. Beech, E. Sigel and A. Puoti, PLoS Pathog.,
2013, 9, e1003524.
14 L. Rufener, P. Maeser, I. Roditi and R. Kaminsky, PLoS
Pathog., 2009, 5, e1000380.
15 R. Van den Brom, L. Moll, C. Kappert and P. Vellema, Vet.
Parasitol., 2015, 209, 278–280.
16 A. Mederos, Z. Ramos and G. Banchero, Parasites Vectors,
2014, 7, 598.
17 A. S. Cezar, G. Toscan, G. Camillo, L. A. Sangioni,
H. O. Ribas and F. S. F. Vogel, Vet. Parasitol., 2010, 173,
157–160.
18 I. Scott, W. E. Pomroy, P. R. Kenyon, G. Smith, B. Adlington
and A. Moss, Vet. Parasitol., 2013, 198, 166–171.
19 J. Hess, M. Patra, L. Rangasamy, S. Konatschnig,
O. Blacque, A. Jabbar, P. Mac, E. M. Jorgensen, R. B. Gasser
and G. Gasser, Chem. – Eur. J., 2016, DOI: 10.1002/
chem.201602851.
Paper Dalton Transactions
17670 | Dalton Trans., 2016, 45, 17662–17671 This journal is © The Royal Society of Chemistry 2016
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 0
4 
O
ct
ob
er
 2
01
6.
 D
ow
nl
oa
de
d 
on
 2
8/
11
/2
01
6 
14
:2
9:
19
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n-
N
on
Co
m
m
er
ci
al
 3
.0
 U
np
or
te
d 
Li
ce
nc
e.
View Article Online
20 J. Hess, M. Patra, V. Pierroz, B. Spingler, A. Jabbar,
S. Ferrari, R. B. Gasser and G. Gasser, Organometallics,
2016, 35, 3369–3377.
21 G. Gasser and N. Metzler-Nolte, Curr. Opin. Chem. Biol.,
2012, 16, 84–91.
22 G. Gasser, I. Ott and N. Metzler-Nolte, J. Med. Chem., 2011,
54, 3–25.
23 G. Jaouen and N. Metzler-Nolte, Topics in Organometallic
Chemistry, Springer, 2010.
24 C. G. Hartinger and P. J. Dyson, Chem. Soc. Rev., 2009, 38,
391–401.
25 P. C. A. Bruijnincx and P. J. Sadler, Curr. Opin. Chem. Biol.,
2008, 12, 197–206.
26 C. Biot, G. Glorian, L. A. Maciejewski, J. S. Brocard,
O. Domarle, G. Blampain, P. Millet, A. J. Georges,
H. Abessolo, D. Dive and J. Lebibi, J. Med. Chem., 1997, 40,
3715–3718.
27 C. Biot and D. Dive, in Medicinal Organometallic Chemistry,
ed. G. Jaouen and N. Metzler-Nolte, Springer-Verlag,
Heidelberg, 2010, vol. 32, pp. 155–193.
28 C. Biot, W. Castro, C. Y. Botte and M. Navarro, Dalton
Trans., 2012, 41, 6335–6349.
29 D. Dive and C. Biot, ChemMedChem, 2008, 3, 383–391.
30 R. Rubbiani, O. Blacque and G. Gasser, Dalton Trans., 2016,
45, 6619–6626.
31 M. Patra, G. Gasser, M. Wenzel, K. Merz, J. E. Bandow and
N. Metzler-Nolte, Organometallics, 2010, 29, 4312–4319.
32 M. Patra, G. Gasser, A. Pinto, K. Merz, I. Ott, J. E. Bandow
and N. Metzler-Nolte, ChemMedChem, 2009, 4, 1930–
1938.
33 M. Patra, K. Ingram, V. Pierroz, S. Ferrari, B. Spingler,
R. B. Gasser, J. Keiser and G. Gasser, Chem. – Eur. J., 2013,
19, 2232–2235.
34 M. Patra, K. Ingram, V. Pierroz, S. Ferrari, B. Spingler,
J. Keiser and G. Gasser, J. Med. Chem., 2012, 55, 8790–
8798.
35 M. Patra, K. Ingram, A. Leonidova, V. Pierroz, S. Ferrari,
M. N. Robertson, M. H. Todd, J. Keiser and G. Gasser,
J. Med. Chem., 2013, 56, 9192–9198.
36 F. Dubar, T. J. Egan, B. Pradines, D. Kuter, K. K. Ncokazi,
D. Forge, J.-F. O. Paul, C. Pierrot, H. Kalamou, J. Khalife,
E. Buisine, C. Rogier, H. Vezin, I. Forfar, C. Slomianny,
X. Trivelli, S. Kapishnikov, L. Leiserowitz, D. Dive and
C. Biot, ACS Chem. Biol., 2011, 6, 275–287.
37 N. Chavain, H. Vezin, D. Dive, N. Touati, J.-F. Paul,
E. Buisine and C. Biot, Mol. Pharmaceutics, 2008, 5, 710–716.
38 N. Gauvry, T. Goebel, P. Ducray, F. Pautrat, R. Kaminsky
and M. Jung, WO05/044784, 2005; Chem. Abstr., 2005, 142,
481750.
39 J. Bernstein, R. E. Davis, L. Shimoni and N. L. Chang,
Angew. Chem., Int. Ed. Engl., 1995, 34, 1555–1573.
40 S. Top, A. Vessières, G. Leclercq, J. Quivy, J. Tang,
J. Vaissermann, M. Huché and G. Jaouen, Chem. – Eur. J.,
2003, 9, 5223–5236.
41 C. Biot, G. Glorian, L. A. Maciejewski and J. Brocard,
J. Med. Chem., 1997, 40, 3715–3718.
42 G. Jaouen, S. Top, A. Vessières, G. Leclercq and
M. J. McGlinchey, Curr. Med. Chem., 2004, 11, 2505–2517.
43 W. L. F. Armarego and D. D. Perrin, Purification of
Laboratory Chemicals, Butterworth-Heinemann, Oxford,
UK, 4th edn, 1996.
44 D. P. Cormode, A. J. Evans, J. J. Davis and P. D. Beer, Dalton
Trans., 2010, 39, 6532–6541.
45 H. E. Gottlieb, V. Kotlyar and A. Nudelman, J. Org. Chem.,
1997, 62, 7512–7515.
46 G. R. Fulmer, A. J. M. Miller, N. H. Sherden, H. E. Gottlieb,
A. Nudelman, B. M. Stoltz, J. E. Bercaw and K. I. Goldberg,
Organometallics, 2010, 29, 2176–2179.
47 Agilent Technologies, Journal, 2014, Xcalibur CCD system.
48 W. Kabsch, Acta Crystallogr., Sect. D: Biol. Crystallogr., 2010,
66, 125–132.
49 S. Bailey, Acta Crystallogr., Sect. D: Biol. Crystallogr., 1994,
50, 760–763.
50 P. R. Evans, Acta Crystallogr., Sect. D: Biol. Crystallogr.,
2011, 67, 282–292.
51 A. Altomare, M. C. Burla, M. Camalli, G. L. Cascarano,
C. Giacovazzo, A. Guagliardi, A. G. G. Moliterni, G. Polidori
and R. Spagna, J. Appl. Crystallogr., 1999, 32, 115–119.
52 G. M. Sheldrick, Acta Crystallogr., Sect. C: Cryst. Struct.
Commun., 2015, 71, 3–8.
53 M. Zakson-Aiken, L. M. Gregory, P. T. Meinke and
W. L. Shoop, J. Med. Entomol., 2001, 38, 576–580.
54 S. E. Wade and J. R. Georgi, J. Med. Entomol., 1988, 25,
186–190.
55 L. Lovis, J. L. Perret, J. Bouvier, J. M. Fellay, R. Kaminsky,
B. Betschart and H. Sager, Vet. Parasitol., 2011, 182, 269–280.
56 L. Lovis, M. C. Mendes, J. L. Perret, J. R. Martins,
J. Bouvier, B. Betschart and H. Sager, Vet. Parasitol., 2013,
191, 323–331.
57 R. Rubbiani, T. N. Zehnder, C. Mari, O. Blacque,
K. Venkatesan and G. Gasser, ChemMedChem, 2014, 9,
2781–2790.
Dalton Transactions Paper
This journal is © The Royal Society of Chemistry 2016 Dalton Trans., 2016, 45, 17662–17671 | 17671
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 0
4 
O
ct
ob
er
 2
01
6.
 D
ow
nl
oa
de
d 
on
 2
8/
11
/2
01
6 
14
:2
9:
19
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n-
N
on
Co
m
m
er
ci
al
 3
.0
 U
np
or
te
d 
Li
ce
nc
e.
View Article Online
